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Abstract: Background: It is essential to study the effect of potential co-factors on the risk of death in 
patients infected by COVID-19. The identification of risk factors is important to allow more efficient 
public health and health services strategic interventions with a significant impact on deaths by 
COVID-19. This study aimed to identify factors associated with COVID-19 deaths in Portugal. 
Methods: A national dataset with the first 20,293 patients infected with COVID-19 between 1 
January and 21 April 2020 was analyzed. The primary outcome measure was mortality by COVID-
19, measured (registered and confirmed) by Medical Doctors serving as health delegates on the daily 
death registry. A logistic regression model using a generalized linear model was used for estimating 
Odds Ratio (OR) with 95% confidence intervals (95% CI) for each potential risk indicator. Results: 
A total of 502 infected patients died of COVID-19. The risk factors for increased odds of death by 
COVID-19 were: sex (male: OR = 1.47, ref = female), age ((56–60) years, OR = 6.01; (61–65) years, OR 
= 10.5; (66–70) years, OR = 20.4; (71–75) years, OR = 34; (76–80) years, OR = 50.9; (81–85) years, OR = 
70.7; (86–90) years, OR = 83.2; (91–95) years, OR = 91.8; (96–104) years, OR = 140.2, ref=(0–55)), 
Cardiac disease (OR = 2.86), Kidney disorder (OR = 2.95), and Neuromuscular disorder (OR = 1.58), 
while condition (None (absence of precondition); OR = 0.49) was associated with a reduced chance 
of dying after adjusting for other variables of interest. Conclusions: Besides age and sex, 
preconditions justify the risk difference in mortality by COVID-19. 
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1. Introduction 
Since December 2019, a pneumonia caused by a novel coronavirus (SARS-CoV-2) has emerged 
around the globe, leading to important health concerns worldwide [1]. 
The most prevalent comorbidities in the Corona Virus Disease 2019 (COVID-19) patients have 
been reported to be hypertension, diabetes, cardiovascular diseases, and respiratory system disorders 
[2]. Between 11 December 2019 and 31 January 2020, of the 1590 cases analyzed by Guan et al. [3] 
25.1% of laboratory-confirmed individuals had at least one comorbidity, with HR of 1.79 (95% CI 
1.16–2.77) among patients with at least one comorbidity and 2.59 (95% CI 1.61–4.17) among patients 
with two or more comorbidities compared with patients without comorbidity. From the 3912 deaths 
that occurred in England and Wales relating to COVID-19 (March 2020), 3563 (91%) had at least one 
pre-existing condition [4]. 
Outcomes such as admission to an intensive care unit (ICU), invasive ventilation, death and 
greater disease severity have been studied in the context of COVID-19 disease [5]. The findings of 
these studies suggested that the majority of patients who had moderate to severe respiratory failure 
required invasive mechanical ventilation and patients with severe illness required admission to the 
ICU. Furthermore, patients with comorbidity are at higher risks for poor outcomes: respiratory 
failure, cardiovascular diseases, diabetes, and kidney injury seem to be highly associated with the 
death of patients with COVID-19 [3,6,7]. Adverse outcomes were also found in older individuals (≥60 
years) [4,7,8] and in males [9] in data from both China and European countries. It is important to 
consider that most studies have been performed in China, which may have different demographic 
characteristics and prevalence of comorbidities compared to the European population, and therefore 
a different effect and impact of risk factors [9]. Data describing underlying health conditions among 
Portuguese patients with COVID-19 have not yet been reported. Limited information has been 
accessible to describe the presence of comorbidities and outcomes in these individuals. 
Globally, there has been an effort to implement several control measures to prevent, prepare, 
and develop integrated policies against COVID-19. The knowledge of the impact of comorbidities on 
possible outcomes will allow a more efficient clinical triage of patients by identifying those at greater 
risk of progression of COVID-19 and more severe complications including death. Furthermore, health 
services can predict more accurately the need for treatments, facilities, equipment, and necessary 
staff, according to the risk of patients with a positive test. Considering no vaccine or antiviral 
treatment for COVID-19 proved effective, public health authorities should prioritize measures and 
activate specific mechanisms for high-risk patients and strategic community-based networks to 
protect vulnerable groups of people before and after diagnostic of COVID-19. 
In the present study, we performed a comprehensive evaluation of a database with 20,293 
COVID-19-infected individuals. The aim of this study was to identify factors and the role of 
preconditions associated with COVID-19 deaths in Portugal from 1 January to 21 April 2020. 
2. Materials and Methods 
2.1. Study Design 
This study consisted of the analysis of an official public dataset provided by the General Health 
Directorate of Portugal (DGS) on 27 April 2020. The dataset is available from the General-Directorate 
of Health in Portugal (DGS), by request and submission of a detailed analysis project and an ethical 
committee authorization to perform research on the dataset [10]. Provision of the dataset is then at 
the discretion of the General Directorate of Health. The data were collected by the SINAVE (National 
System for Epidemiological Surveillance), which is the national database for mandatory diseases and 
public health problems notifications, managed by DGS, that provided the data fully anonymized. 
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The research team filled the publicly available form and submitted an analysis project. The project 
was approved by an Ethics Committee (number 165/2020). 
2.2. Data Collected 
The provided data concern information between 1 January and 21 April 2020 on infected cases 
and deaths by COVID-19. A confirmed case was based on a positive polymerase chain reaction test. 
The primary outcome measure was mortality by COVID-19, measured (registered and confirmed) by 
Medical Doctors serving as health delegates on the daily death registry. The dataset received on 27 
April, encompasses confirmed deaths up to 21 April. Potential deaths from cases registered later in 
the database (in particular between early April and 27 April) are not confirmed and accounted for in 
the dataset. 
As referenced above, the data were registered in SINAVE, an electronic system for 
epidemiological surveillance of mandatory diseases that includes laboratory notification. SARS-CoV-
2 cases are registered by doctors in SINAVE allowing the electronic communication with local, 
regional, and national health authorities [11]. The SARS-CoV-2 case definition used is based on the 
World Health Organization case definition. 
The SINAVE allows epidemiological surveillance and epidemiological data registration 
including laboratory notification, ongoing treatment, hospitalization, existing health preconditions 
(morbidity), and death registration. 
Individualized health precondition indicator variables were constructed from the two variables 
provided in the database (“precondition” and “other precondition”). 
2.3. General Characteristics and Outcome  
The data retrieved include individuals’ demographic characteristics (age, sex, region), COVID-
19 disease information (death, recovery, still in treatment, hospitalization, intensive care, respiratory 
support), and preconditions (Asthma, Cancer, Cardiac disease, Hematological disorder, Diabetes, 
HIV and other immune deficiency, Kidney disorder, Liver disorder, Neuromuscular disorder, Other 
precondition and None (absence of precondition)). The data on intensive care and respiratory support 
include a number of individuals with “unknown” status that we considered to not have had these 
interventions if they were never hospitalized. This work considers as primary outcome mortality 
among those with a positive molecular test for COVID-19 on record. 
2.4. Statistical Analysis 
Descriptive statistics, such as absolute and relative frequencies, mean, standard deviations, and 
medians were used to summarize univariate characteristics. 
Bivariable analyses were performed between the outcome variable (death) and variables 
potentially associated using the X2 test or the Fisher exact test. Further bivariate analysis was 
performed to evaluate the difference in distribution between preconditions and sex, hospitalization, 
and intensive care. 
We analyzed regional differences based on the second level of the Nomenclature of Territorial 
Units for Statistical purposes (NUTS II) classification for Portugal. 
Logistic regression models were performed using a generalized linear model with binomial 
error distribution and logit link function to estimate the crude and adjusted Odds Ratio (OR) with 
95% confidence intervals (95% CI) for each potential risk factor. The model performance was assessed 
using the area under the curve (AUC) and corresponding 95% confidence intervals (95% CI). The 
significance level was set at 5%. Statistical analysis was performed using R software version 3.6.3 (R 
Foundation for Statistical Computing, Vienna, Austria). 
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3. Results 
3.1. Characteristics of Infected Individuals 
The available information comprises all 20,293 individuals reported as infected with SARS-CoV-
2 in Portugal between 1 January and 21 April 2020. There were 11,903 female (58.7%) and 8390 male 
cases (41.3%). The average age (standard deviation) of the individuals was 52.1 years (21.3 years), 
with a majority between 18 and 55 years of age (57.2%, minimum: 0 years; maximum: 104 years). The 
majority of cases (60%) occurred in the North region (Table 1). Considering the geographical region, 
the distribution of infection rates per 100,000 inhabitants was the following: 341.8 in the North region 
(12,211 individuals infected in a population of 3,572,583); 107.6 in the Algarve region (472 individuals 
infected in a population of 438,864); 127.1 in the Center region (2817 individuals infected in a 
population of 2,216,569); 149.8 in the Lisbon Metropolitan region (4264 individuals infected in a 
population of 2,846,332); 55.4 in the Alentejo region (391 individuals infected in a population of 
705,478); 18.9 in the Madeira region (48 individuals infected in a population of 253,945); and 37.1 in 
the Azores region (90 individuals infected in a population of 242,846). 
In terms of health preconditions, the most common observed condition was Diabetes (5.1%), 
followed by Neuromuscular (3.4%) and Lung disorders (3.4%). 
Table 1. Characteristics of the SARS-CoV-2 infected individuals and corresponding lethality in 
Portugal on 21 April 2020. 
Variable  n(%) Deaths (%) p-Value * 
Outcome Recovered 1244 (6.1%)   
 Died COVID-19 502 (2.5%)   
 Ongoing Treatment 18524 (91.3%)   
 Unknown 23 (0.1%)   
Sex Female 11903 (58.7%) 253 (2.13%) <0.001 
 Male 8390 (41.3%) 249 (2.97%)  
Age (0,18) 711 (2.5%) 0 (0%) <0.001 
 (19,35) 4153 (20.5%) 0 (0%)  
 (36,45) 3259 (16.1%) 3 (0.09%)  
 (46,55) 3653 (18.1%) 10 (0.27%)  
 (56,65) 3046 (15.1%) 30 (0.98%)  
 (66,75) 1926 (9.5%) 78 (4.05%)  
 (76,85) 1864 (9.2%) 177 (9.50%)  
 86+ 1618 (8.0%) 204 (12.61%)  
Region North 12211 (60.2%) 319 (2.61%) 
<0.001 
 Algarve 472 (2.3%) 6 (1.27%) 




4264 (21.0%) 74 (1.74%) 
 Alentejo 391 (1.9%) 6 (1.53%) 
 Madeira 48 (0.2%) 0 (0%) 
 Azores 90 (0.4%) 0 (0%) 
Hospitalization No 15697 (77.4%) 126 (0.80%) <0.001 
 Unknown 1623 (8.0%) 46 (2.83%)  
 Yes 2973 (14.7%) 330 (11.10%)  
Intensive Care No 15697 (77.4%) 126 (0.80%) <0.001 
 Unknown 4335 (21.4%) 475 (10.96%)  
 Yes 261 (1.3%) 27 (10.34%)  
Respiratory 
Support 
No 1315 (6.5%) 156 (11.86%) <0.001 
 Oxygen 59 (0.3%) 0 (0%)  
 Ventilator 26 (0.1%) 0 (0%)  
 Unknown 18893 (93.1%) 346 (1.83%)  
Precondition     
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Asthma  Presence 277 (1.4%) 3 (1.08%) 0.192 
 Absence 20016 (98.7%) 499 (2.50%)  
Cancer  Presence 611 (3.0%) 47 (7.69%) <0.001 
 Absence 19682 (97.0%) 455 (2.3%)  
Cardiac Disease Presence 54 (0.3%) 19 (35.2%) <0.001 
 Absence 20239 (99.7%) 483 (2.4%)  
Hematological 
Disorder 
Presence 220 (1.1%) 29 (13.2%) <0.001 
 Absence 20073 (98.9%) 473 (2.4%)  
Diabetes Presence 1145 (5.6%) 83 (7.3%) <0.001 
 Absence 19148 (94.4%) 419 (2.2%)  
HIV/other Immune 
Deficiency  
Presence 107 (0.5%) 6 (5.6%) 0.075 
 Absence 20186 (99.5%) 496 (2.5%)  
Kidney Disorder  Presence 401 (2.0%) 98 (24.4%) <0.001 
 Absence 19892 (98.0%) 404 (2.0%)  
Liver Disorder  Presence 107 (0.5%) 7 (6.5%) 0.016 
 Absence 20186 (99.5%) 495 (2.5%)  
Lung Disorder  Presence 688 (3.4%) 60 (8.7%) <0.001 
 Absence 19605 (96.6%) 442 (2.3%)  
Neuromuscular 
Disorder 
Presence 795 (3.9%) 123 (15.5%) <0.001 
 Absence 19498 (96.1%) 379 (1.9%)  
Other Condition  Presence 76 (0.4%) 4 (5.3%) 0.231 
 Absence 20217 (99.6%) 498 (2.5%)  
None  No Precondition 16927 (83.4%) 212 (1.3%) <0.001 
(Absence of 
Precondition) 
At least one 
Precondition 
3366 (16.6%) 290 (8.6%)  
* The p-value refers to the comparison between mortality proportions. 
3.2. Mortality Among the Infected 
There are 502 deaths registered in the database representing an overall lethality of 2.5% of all 
infected cases at that point (note that cases registered later in the database may not have their final 
outcome yet). Among the deceased, the mean age was 81.5 ± 10.5 and median 84 years, while in the 
group that recovered or was still in treatment, mean age was 51.3 ± 21.0 years. 
From the available information, at least 2973 (14.7%) infected cases were hospitalized (the data 
include 1623 cases with unknown hospitalization status), at least 261 (1.3%) infected cases were 
subjected to intensive care, and at least 86 (0.4%) had respiratory support (oxygen or ventilator). 
Mortality within the hospitalized cases was 11.1% (330), within those subjected to intensive care 
10.3% (27). At this point, no deaths were registered among those submitted to respiratory support 
(Table 1). 
Lethality was higher in men (2.97%) than in women (2.13%). Lethality increased with age 
reaching 9.5% in infected cases aged 75 to 85 and 12.61% in infected cases older than 85 years old. 
Considering the geographical region, the highest lethality was observed in the Centre region 
with 3.44% (97 deaths), followed by the North region with 2.61% (319 deaths) and Lisbon 
Metropolitan Area with 1.74% (74 deaths). 
3.3. Association Between Characteristics and Lethality 
Most of the preconditions were significantly associated, in bivariate analyses, with the death 
outcome (lethality), with increased lethality in those carrying the precondition. The highest lethality 
was observed among those infected with a prior history of Cardiac and Kidney disorders (Table 1). 
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3.4. Other Associations with Health Precondition 
The results of the analyses between preconditions and sex, hospitalization, and intensive care 
are depicted in Table 2. Most preconditions were significantly more prevalent in men (except for 
Asthma and None). Hospitalization of infected cases was associated, albeit weakly, with all 
preconditions. Cardiac disease, Kidney, Neuromuscular, and Hematological disorders had higher 
chances of hospitalization. Most preconditions were associated with the use of intensive care, with 
Cardiac disease, Kidney disease, HIV/other immune deficiency, Lung disease, and Diabetes with 
higher chances of being submitted to intensive care. 
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1 Reference- Female; 2 Reference- Hospitalization: No; 3 Reference- Intensive care: Unknown. 
3.5. Factors Associated with Lethality 
The univariable and multivariable logistic regression analysis for the outcome “death” in 
infected patients with COVID-19 is shown in Table 3 and Figure 1. Table 3 registers three 
multivariable models: Model 1, a model only including patients without preconditions; Model 2, for 
each individual precondition adjusted for age and sex; Model 3, the full model. Considering the full 
multivariable model, males exhibited a 47% increase in mortality compared to female patients. 
Concerning age, an overall “J” shape along age was defined by the given parameters (odds ratios). 
After adjusting for the remaining variables, a less defined “J” shape results. This still means that 
lethality risk increases with the infected cases’ age after adjustment. Considering the preconditions, 
the majority were bivariately associated with mortality. After adjustment, three preconditions 
(Cardiac disease, Kidney disease, Neuromuscular disorder, and None (absence of precondition)) 
remained significantly associated. The presence of Cardiac disease and Kidney disease in the infected 
cases doubled the chance of mortality by COVID-19. The absence of preconditions (None) showed a 
protective effect, reducing the chance of mortality by COVID-19. Complementary calculations 
(multivariable models) were performed with the objective of evaluating the data robustness and 
model consistency (Table 4). First, we analyzed a model excluding data from the last 3 weeks so that 
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cases with insufficient follow-up were excluded. Next, we analyzed a model including only the 
Hospitalized cases, assuming that these cases would have more accurate recording of comorbidities. 
As shown in Table 4, the results of these two reduced models are consistent with the model for the 
full dataset in Table 3 
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Table 3. Univariable and Multivariable logistic regression analyses for the outcome “death” in infected individuals with COVID-19. 
Variables 
Odds Ratio  
(OR)  
Crude Values  
(95% CI) ^ 
p-Value 
Odds Ratio  
(OR)  
Adjusted Values  
(95% CI) 1 
p-Value 
Odds Ratio  
(OR)  
Adjusted Values  
(95% CI) 2 
p-Value 
Odds Ratio  
(OR)  
Adjusted Values  
(95% CI) 3 
p-Value 
Sex         
Female 1.0 (reference)  1.0 (reference)    1.0 (reference)  
Male 1.41 (1.17;1.69) p < 0.001 1.99 (1.49;2.65) <0.001   1.47 (1.20;1.79) <0.001 
Age (0–55) years 1.0 (reference)  1.0 (reference) <0.001   1.0 (reference)  
Age (56–60) years 6.50 (2.92; 14.36) p < 0.001 13.20 (3.23;64.41) <0.001   6.01 (2.68;13.40) <0.001 
Age (61–65) years 12.25 (6.02; 25.59) p < 0.001 29.57 (8.81;133.44) <0.001   10.50 (5.12;22.17) <0.001 
Age (66–70) years 26.53 (13.98; 53.09) p < 0.001 53.71 (16.72;237.98) <0.001   20.36 (10.59;41.31) <0.001 
Age (71–75) years 51.22 (28.60; 98.67) p < 0.001 115.37 (39.16;492.19) <0.001   34.01 (18.64;66.69) <0.001 
Age (76–80) years 80.27 (45.75; 152.50) p < 0.001 187.76 (65.80;789.55) <0.001   50.91 (28.46; 98.50) <0.001 
Age (81–85) years 108.56 (63.20; 203.27) p < 0.001 281.18 (102.16;1162.9) <0.001   70.65 (40.35;134.69) <0.001 
Age (86–90) years 125.87 (73.28; 235.68) p < 0.001 357.87 (130.42;1478.17) <0.001   83.23 (47.51;58.70) <0.001 
Age (91–95) years 125.67 (71.30; 239.55) p < 0.001 407.45 (145.58;1698.79) <0.001   91.83 (51.10;178.31) <0.001 
Age (96–104) years 183.30 (94.32; 374.16) p < 0.001 640.17 (203.95;2818.60) <0.001   140.17 (70.69;291.53) <0.001 
Asthma 0.03 (0.02; 0.03) p = 0.145   0.80 (0.19;2.21) 0.740 0.54 (0.13;1.51) 0.305 
Cancer 3.52 (2.55; 4.76) p < 0.001   1.48 (1.06;2.04) 0.018 0.92 (0.64;1.32) 0.666 
Cardiac Disease 22.20 (12.38; 38.65) p < 0.001   6.40 (3.48;11.51) <0.001 2.86 (1.51;5.32) <0.001 
Chronic Hematological Disorder 6.29 (4.13; 9.24) p < 0.001   2.33 (1.50;3.51) <0.001 1.21 (0.73;1.95) 0.447 
Diabetes 3.49 (2.72;4.43) p < 0.001   1.39 (1.08;1.79) 0.010 0.75 (0.55;1.01) 0.057 
HIV/Other Imune Deficiency 2.36 (0.92 4.95) p = 0.042   3.12 (1.15;7.19) 0.014 1.48 (0.53;3.52) 0.414 
Kidney Disorder 15.60 (12.13;19.93) p < 0.001   4.97 (3.80;6.46) <0.001 2.95 (2.16;4.00) <0.001 
Liver Disorder 2.79 (1.17;5.60) p = 0.010   1.77 (0.72;3.76) 0.168 0.88 (0.35;1.94) 0.773 
Lung Disorder 4.14 (3.10;5.44) p < 0.001   1.79 (1.32;2.39) <0.001 1.05 (0.75;1.47) 0.761 
Neuromuscular Disorder 9.23 (7.41;11.44) p < 0.001   2.67 (2.11;3.34) <0.001 1.58 (1.17;2.14) 0.003 
None 0.14 (0.11;0.16) p < 0.001   0.34 (0.28;0.41) <0.001 0.49 (0.35;0.68) <0.001 
Other condition 2.20 (0.67;5.33) p = 0.126   1.31 (0.38;3.43) 0.625 0.88 (0.23;2.74) 0.341 
^ Univariable analyses; 1 Model including only individuals without preconditions; 2 Model for each individual precondition adjusted for Age and Sex; 3 Full model 
adjusted for Pregnancy. 
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Figure 1. Forest plot illustrating the contribution of each co-factor for the overall model. 
Table 4. Complementary calculations to evaluate data robustness and model consistency: A 
multivariable model only including cases up to 31 March 2020 and a multivariable model for 
hospitalized cases. 
Variables 
Odds Ratio  
(OR)  
Adjusted Values  
(95% CI) * 
p-Value 
Odds Ratio  
(OR)  
Adjusted Values  
(95% CI) ** 
p-Value 
Sex     
Female 1.0 (reference)  1.0 (reference)  
Male 1.59 (1.24; 2.06) <0.001 1.05 (0.81;1.35) =0.713 
Age (0–55) years 1.0 (reference)  1.0 (reference)  
Age (56–60) years 8.29 (3.41; 20.77) <0.001 2.94 (1.13;7.56) =0.024 
Age (61–65) years 12.26 (5.40; 29.52) <0.001 2.53 (1.01;6.37) 0.045 
Age (66–70) years 21.76 (10.05; 51.01) <0.001 3.96 (1.78;9.33) <0.001 
Age (71–75) years 37.94 (18.68;85.59) <0.001 5.62 (2.76;12.53) <0.001 
Age (76–80) years 67.09 (33.77; 149.30) <0.001 8.37 (4.22;18.34) <0.001 
Age (81–85) years 92.48 (47.10;204.31) <0.001 12.82 (6.65;27.55) <0.001 
Age (86–90) years 141.25 (71.63;313.08) <0.001 14.22 (7.33;30.72) <0.001 
Age (91–95) years 174.32 (83.94;400.32) <0.001 14.77 (7.25;33.00) <0.001 
Age (96–104) years 347.63 (140.08;913.73) <0.001 18.32 (7.37;46.94) <0.001 
Asthma 1.01 (0.23;3.09) =0.994 0.38 (0.02;2.00) =0.363 
Cancer 1.02 (0.64;1.59) =0.939 0.98 (0.64;1.48) =0.930 
Cardiac Disease 2.09 (0.99;4.25) =0.046 2.14 (1.09;4.09) =0.024 
Chronic Hematological Disorder 0.96 (0.49;1.79) =0.907 1.53 (0.89;2.56) =0.118 
Diabetes 0.63 (0.42;0.94) =0.027 0.69 (0.49;0.98) =0.040 
HIV/other imune deficiency 2.17 (0.74;5.59) =0.129 1.27 (0.40;3.32) =0.650 
Kidney Disorder 1.98 (1.35;2.91) <0.001 2.84 (1.99;4.04) <0.001 
Liver Disorder 1.79 (0.49;5.18) =0.324 0.88 (0.34;1.98) =0.779 
Lung Disorder 1.04 (0.69;1.57) =0.844 0.97 (0.64;1.44) =0.872 
Neuromuscular Disorder 1.44 (0.98;2.11) =0.065 1.39 (0.98;1.97) =0.066 
None 0.59 (0.38;0.90) =0.014 0.84 (0.55;1.27) =0.394 
Other condition 1.05 (0.14;5.00) =0.960 0.57 (0.12;2.04) =0.426 
* Full model with cases up to 31 March (n = 11103 individuals; n = 328 deaths); ** Model of 
Hospitalized cases (n = 2973 individuals; n = 230 deaths). 
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The full model performance for predicting COVID-19 mortality is illustrated in Figure 2, where 
an excellent discrimination capacity was observed (AUC (95% CI): 0.909 (0.900;0.919)). 
 
Figure 2. The area under the curve illustrating the performance of the full model to predict mortality 
by COVID-19. Note the high precision given by the area under the curve (AUC) (95% CI) of 0.909 
(0.900;0.919). 
4. Discussion 
Our study evaluating a national database of more than 20,000 infected individuals constitutes 
one of the largest population studies on COVID-19 to date. A total of 14.7% of patients needed 
hospitalization, associated with a case fatality rate (CFR) of 11.1%, while 1.3% were admitted to the 
intensive care unit (ICU) with an associated CFR of 10.3%. These figures were somewhat lower when 
compared to previous systematic reviews, where a 20.3–29.3% and 6.8–13.7% of ICU admission and 
CFR were reported, respectively [12,13]. This difference may be related with a different stage of the 
epidemic in Portugal at the time of data analysis, and differences in the timing of non-pharmaceutical 
actions (schools and medical faculties closures and lockdown declared one and two weeks after the 
first COVID-19 case, respectively) [14], as the majority of studies included in the systematic reviews 
were from China. Moreover, it is important to consider the variations of proportions that were found 
in other individual studies. 
This study represents one of the first attempts to understand the lethality of COVID-19 in 
Portugal from infected cases, proposing risk factors based on multivariable analysis. The risk factors 
for lethality by COVID-19 were sex (male), advanced age, Kidney disorder, Cardiac disease and 
Neuromuscular disorder, while the absence of a precondition was associated with a reduced chance 
of mortality after adjusting for other variables of interest. The principal risk factors for lethality by 
COVID-19 reported in the present study are supported by the literature. The majority of studies 
report male patients, older patients, and patients with preconditions at an increased risk of infection 
and mortality irrespective of the region of the globe [12,15]. A recent meta-analysis of thirteen studies 
registered male individuals (OR = 1.76), age over 65 years old (OR = 6.06), smoking habits (OR = 2.51), 
and preconditions including Cardiovascular disease (OR = 5.19), Diabetes (OR = 3.68), Respiratory 
disease (OR = 3.68), and hypertension (OR = 2.72) as significantly higher in critical/mortal patients 
compared to non-critical patients [15]. Men registered a 48% increased risk of death by COVID-19 in 
our study, a result previously observed [9]. We registered an increased prevalence of preconditions 
in men when compared to women (all preconditions except Asthma); while the absence of 
preconditions was 30% more likely in female individuals. Moreover, the fact that women could have 
stronger responses than men in many infectious pathogens [16], the likelihood of women to search 
for health care services more than men [17], and in the adoption of hygiene practices [18] may further 
complement the explanation of this result. 
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Age was an important predictor for mortality in our study, with lethality-adjusted ORs 
increasing after 55 years of age. Moreover, there was a thirty-year difference in the average age 
between fatal (average age of 81 years) and non-fatal cases (average age of 51 years). Age was a 
predictor for mortality in patients both with and without preconditions, a result supported by a 
previous multicenter cohort study of 191 individuals where increased odds of in-hospital death were 
associated with older age (odds ratio 1.10, 95% CI 1.03–1.17, per year increase [19]). These results are 
partially explained by the increased burden of pre-conditions in older age groups, where dramatic 
increases for the prevalence of preconditions (particularly for Cardiac disease, Kidney disorder, and 
Neuromuscular disorder) were registered in older age groups when compared to individuals of less 
than 55 years of age. Nevertheless, age remained a risk factor for death in our study even in patients 
without preconditions, as would be expected given that advanced age is a risk factor for death even 
in the absence of COVID-19 infection. Indeed, it is possible that the increase in risk of death is more 
due to aging than to COVID-19 infection proper. Still, the link between older individuals and the 
likelihood to develop severe and critical cases of COVID-19 has been made before, either due to 
immunosenescence, malnutrition, or ignoring more easily the early symptoms and consequently 
missing the best time to seek medical advice [20,21]. Furthermore, several studies registered an 
important association between increased age and COVID-19 severity/fatality [22–26]. The 
vulnerability of elderly individuals is illustrated in recent studies. A retrospective observational 
study investigating mortality in hospitalized patients with COVID-19 registered the great 
vulnerability of patients residing in retirement homes, with older age independently associated with 
mortality when adjusted for other variables of interest [22]. On the opposite residence condition, the 
shape of COVID-19 vulnerability was estimated based on a random infection of 10% of the population 
living in private households (excluding individuals living in retirement homes) of 81 countries [27]. 
In this study, it was estimated that national age and coresidence patterns can alter the vulnerability 
of a country to COVID-19 outbreaks, with direct effects dependent on a country’s age structure and 
indirect effects dependent on the size and age structure of a country’s households [27]. 
The specific comorbidities that emerged as risk factors for mortality in our study (Cardiac 
disease, Kidney disorder, and Neuromuscular disorder) should be interpreted considering the 
COVID-19 physiopathology. In our study, the prevalence of Kidney disease on admission in patients 
with COVID-19 was high and associated with clinical stage decline. The highest in-hospital mortality 
rate (24.4%) and chances of mortality (2.43-fold increase) were registered for individuals with Kidney 
disease precondition. Other studies in patients with Kidney disorders recorded comparable results. 
A meta-analysis of eleven COVID-19 studies registered an association between acute Kidney injury 
and a higher risk of mortality of almost 16-fold (OR = 15.93), with creatinine levels significantly higher 
in non-survivors compared to survivors [28]. Nevertheless, the meta-analysis reported a high 
heterogeneity and a difficulty in adjusting for confounders [28]. Pathophysiological mechanisms may 
be involved. Considering that CO2 is an independent determinant of pH adjusted by alveolar 
ventilation, the disturbance of the acid–base regulation (through the interplay of bicarbonate buffer 
and respiratory and renal systems) may induce acid–base imbalance and in this way may pose a life-
threatening situation [29]. A second hypothesis consists in the direct Kidney infection by SARS-CoV-
2, which recognizes the human Angiotensin-converting enzyme 2 as a cellular receptor that allows it 
to infect different host cells, a mechanism previously expressed by SARS-CoV virus [30]. This 
mechanism could explain the particular importance of acute Kidney injury during hospitalization, 
considering the exhibited conditions of proteinuria; hematuria; and elevated levels of either serum 
creatinine, blood urea nitrogen, or both, rendering a significant increase of in-hospital mortality 
between 1+ and 5.5-fold [31]. 
Patients with cardiovascular disorder exhibited a nearly 3-fold increase in the chance of dying 
from COVID-19. Cardiovascular disease has been consistently reported as one of the main risk factors 
for COVID-19 mortality. Two recent meta-analysis reported an odds ratio (95% CI) of 5.19 (3.25; 8.29) 
(1) and a risk ratio (95% CI) of 2.25 (1.53; 3.29)) for mortality in cardiovascular disease patients [32]. 
Our results are in concordance with the systematic review by Pranata et al. [32] and lower than the 
systematic review of Zheng et al. [15]. A possible reason may be the small study effect on the estimates 
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from Zheng et al. [15], considering the majority of the 13 studies included were of smaller sample size 
compared to both our study and Pranata et al. [32]. Nevertheless, the direction of the estimate 
towards risk is clear. The pathophysiological mechanisms behind this association may be multiple: 
from severe infection with SARS-CoV-2, precipitating myocardial infarction, myocarditis, heart 
failure, and arrhythmias as well as an acute respiratory distress syndrome and renal failure [33,34]; 
through the evolution along with multiorgan failure directly due to SARS-CoV-2-infected endothelial 
cells and resulting endothelitis [33]; to the potential impacts of therapies considering the likely 
increase in the number of ACE 2 receptors and the corresponding increase in the susceptibility [33]. 
Furthermore, the link between pneumonia and cardiovascular complications should be accounted 
for: recent studies explore/registered myocardial injury during SARS-CoV-2, secondary to type 2 
myocardial infarction, a consequence of increased oxygen demand or reduced oxygen supply during 
respiratory failure [34–36]. In this scenario, cytokines microvascular activation can cause not only 
myocardial injury but also harm other systems involved in COVID-19 infections, including the 
kidneys [37]. Consequently, the relation between cardiovascular disease, Kidney disease and 
Diabetes should not be ruled out [33,38]. 
Patients with Neuromuscular disorders registered a 41% increase in lethality. The 
pathophysiological mechanisms related to this association could be: (i) the fact that patients with this 
precondition are under the use of immunosuppressive therapies and therefore more likely to increase 
the severity of COVID-19 infection [39]; and (ii) risk of exacerbation of myasthenia gravis and QT 
prolongation in patients with pre-existing cardiac involvement secondary to the treatment with 
hydroxychloroquine and azithromycin [40]. However, given that the present database did not 
provide the patient-specific pharmacological therapies, this question remains open. 
Diabetes, previously registered as a significant risk factor for COVID-19 mortality [3], was not 
significant in our study when adjusted for other variables of interest. A potential reason for this result 
might be related to the level of glycemic control. A recent study evaluating the impact of blood 
glucose control and outcomes of COVID-19 in pre-existing type 2 diabetes noted that when adjusting 
the model for well-controlled blood glucose, a marked lower mortality was registered compared to 
individuals with poorly controlled blood glucose [41]. Data from a national study in Portugal with 
1688 individuals reported about 82% of Portuguese diabetics were pharmacologically medicated and 
that 60.7% were controlled [42]. However, since we were not able to retrieve the level of glycemic 
control in diabetic individuals in our study, this question remains open. 
The strengths of this study include being a population-based study, the large sample size, and 
the origin of the data. SINAVE is the electronic platform for notification and cases monitoring of 
mandatory communicable diseases, allowing the analysis and evaluation of emergent situations, 
particularly large-scale epidemic outbreaks and pandemics, such as a COVID-19. This system allows 
for the electronic articulation of doctors (who notify cases of illness), health authorities (responsible 
for epidemiology at local, regional and national levels), and laboratories (cases notification and cases 
confirmation). SINAVE allows real-time notification, admitting the implementation of control 
measures to control and limit the spread of disease and the occurrence of additional cases. The 
SINAVE database is relevant for the present COVID-19 study by its quality and extensibility since it 
is based on the information registered by the Medical Doctor who notified the case. Furthermore, it 
contains all the notified cases up to the extraction of the data due to the interoperability characteristics 
between the SINAVE computer application and clinical process computer applications. 
The limitations of the present study include the absence of potentially important data from the 
database, missing data, underreporting of mild cases, the impossibility of accounting for the temporal 
sequence of events, and under-reporting of preconditions. The limitations are presented and 
discussed in detail below, including the potential bias and corresponding direction. The database did 
not include reported symptoms and laboratory test results. The existence of unknown values in the 
data for some outcomes, together with the reporting of preconditions in the medical record, may lead 
to an underestimation of some risk indicators. It is likely that some of the preconditions were under-
reported both in quantity and importance: a particular example is cerebrovascular disease, 
considered one of the comorbidities with significant impact in COVID-19 prognostic [7], and 
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conspicuously absent from our database. The temporal sequence of events was not taken into account 
(time elapsed between the onset of symptoms and hospital admission, or time between hospital 
admission and death), which may imply an underestimation of preconditions. Finally, because the 
patients’ clinical observation is still ongoing, many individuals have not reached clinical endpoints 
(recovery or death). The authors performed complementary calculations to evaluate data robustness 
and model consistency: The results of these complementary estimations (one model excluding cases 
from the last 3 weeks and the other model on hospitalized cases) show reasonable consistency with 
the full multivariable model. A further limitation is related to the data that concern only the initial 
phase of the pandemic in Portugal up to 21 April. The pandemic is still ongoing, registering on June 
25 about 40,866 infected individuals and 1555 deaths [43]. Nevertheless, no update of the data was 
made available up to the moment, and therefore the hypothesis of a difference in mortality between 
the initial and actual phase remains open. 
The results of the present study registered potential different pathophysiological mechanisms 
for COVID-19 mortality, suggesting the need for a team approach between different medical 
specialties in order to maximize the probabilities of recovery for COVID-19 patients. Future research 
with larger data sets should include the study of effect and impact of preconditions with individuals 
reaching clinical endpoints to gain a better understanding of risk factors, as well as the economic and 
health impacts of COVID-19. 
5. Conclusions 
Based on the results, lethality by COVID-19 in Portuguese infected individuals was significantly 
associated with demographics (males; advanced age) and the preconditions Cardiac disease, Kidney 
disease, and Neuromuscular disorder. The present study successfully modeled the condition to 
assess the prognosis of each patient with high precision. Being one of the first studies in Europe not 
only to identify the main preconditions associated with COVID-19 lethality but also to include a 
model for individuals with absence of preconditions in more than 20,000 cases, this research thus 
represents a potential important benchmark for future studies. 
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